CoChat
Cited by 203

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

Open access
Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J. · 2017 · European Urology

Abstract

Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomized trial. Objective To evaluate the relationship between tumor mutations and treatment outcomes in RECORD-3, a randomized trial comparing first-line everolimus (mTOR inhibitor) followed by sunitinib (VEGF inhibitor) at progression with the opposite sequence in 471 metastatic RCC patients. Design, setting, and participants Targeted sequencing of 341 cancer genes at ~540× coverage was performed on available tumor samples from 258 patients; 220 with clear cell histology (ccRCC). Outcome measurements and statistical analysis Associations between somatic mutations and median first-line progression free survival (PFS1L) and overall survival were determined in metastatic ccRCC using Cox proportional hazards models and log-rank tests. Results and limitations Prevalent mutations (≥ 10%) were VHL (75%), PBRM1 (46%), SETD2 (30%), BAP1 (19%), KDM5C (15%), and PTEN (12%). With first-line everolimus, PBRM1 and BAP1 mutations were associated with longer (median [95% confidence interval {CI}] 12.8 [8.1, 18.4] vs 5.5 [3.1, 8.4] mo) and shorter (median [95% CI] 4.9 [2.9, 8.1] vs 10.5 [7.3, 12.9] mo) PFS1L, respectively. With first-line sunitinib, KDM5C mutations were associated with longer PFS1L (median [95% CI] of 20.6 [12.4, 27.3] vs 8.3 [7.8, 11.0] mo). Molecular subgroups of metastatic ccRCC based on PBRM1, BAP1, and KDM5C mutations could have predictive values for patients treated with VEGF or mTOR inhibitors. Most tumor DNA was obtained from primary nephrectomy samples (94%), which could impact correlation statistics. Conclusions PBRM1, BAP1, and KDM5C mutations impact outcomes of targeted therapies in metastatic ccRCC patients. Patient summary Large-scale genomic kidney cancer studies reported novel mutations and heterogeneous features among individual tumors, which could contribute to varied clinical outcomes. We demonstrated correlations between somatic mutations and treatment outcomes in clear cell renal cell carcinoma, supporting the value of genomic classification in prospective studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.10.007

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 203

Metadata

Authors
Hsieh, J. J., Chen, D., Wang, P. I., Marker, M., Redzematovic, A., Chen, Y.-B., Selcuklu, S. D., Weinhold, N., Bouvier, N., Huberman, K. H., Bhanot, U., Chevinsky, M. S., Patel, P., Pinciroli, P., Won, H. H., You, D., Viale, A., Lee, W., Hakimi, A. A., Berger, M. F., Socci, N. D., Cheng, E. H., Knox, J., Voss, M. H., Voi, M., & Motzer, R. J.
Venue
European Urology
Publisher
Elsevier BV
Published
2017-03
Volume
71
Issue
3
Pages
405-414
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2534471526
Cited by
203
References
4
FWCI
20.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1016/j.eururo.2016.10.007
The paper
Hsieh, J. J., Chen, D., Wang, P. I., Marker, M., Redzematovic, A., Chen, Y.-B., Selcuklu, S. D., Weinhold, N., Bouvier, N., Huberman, K. H., Bhanot, U., Chevinsky, M. S., Patel, P., Pinciroli, P., Won, H. H., You, D., Viale, A., Lee, W., Hakimi, A. A., . . . Motzer, R. J. (2017). Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology. https://doi.org/10.1016/j.eururo.2016.10.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.